MLMichael Masao Lindeborg

Michael Masao Lindeborg

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael Masao Lindeborg has a total of 84 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Patient Navigation on Time to Intervention for Deaf and Hard‐of‐Hearing Children

    by Michael M. Lindeborg, Kendyl Naugle, Michelle A. Wong, Inderpreet K. Khalsa, Jihyun R. Stephans, Sarah Coulthurst, Joy Kearns, Dylan K. Chan

    Objective: Early identification of pediatric hearing loss is crucial for development. Only 44.5% of deaf and hard‐of‐hearing (DHH) children are enrolled in early intervention by the recommended age of 6 months. This study evaluated the impact of a patient navigator on time to intervention for pediatric hearing loss. Study Design: Pre‐post cohort study. Setting: Tertiary children's hospital. Methods: We compared a prospective cohort of newly‐identified DHH children who received the Patient Navigator Intervention to a retrospective preintervention cohort. Study endpoints included time to (1) Enrollment in Part C Early Intervention (education intervention); (2) Medical clearance for amplification; (3) Hearing aid fitting or cochlear implant activation. Results: 76 newly‐identified DHH children received the Patient Navigator Intervention and 47 children did not. Children who received the intervention had a significantly shorter time to Early Intervention enrollment (36 vs 77 days, P = .011) and medical clearance for amplification (18 vs 53 days, P = .001). This remained significant after controlling for hearing loss severity and neighborhood disadvantage. There was no difference in time to medical intervention. Race, household language, or health insurance were not associated with delays. The intervention was associated with a higher proportion who received timely medical clearance (55.0% vs 81.8%, P = .003) and enrollment in Early Intervention (57.1% vs 82.9%, P = .013). Conclusions: A patient navigator significantly decreased the time from hearing loss identification to educational intervention and medical clearance. Additionally, the intervention increased the proportion who achieved Early Intervention services in accordance with nationally recognized Early Hearing Detection and Intervention quality milestones.


  • Risk Factors Associated with Delays in Hearing Loss Identification in Pediatric Patients

    by Michael M. Lindeborg, Inderpreet Kaur Khalsa, Elizabeth N. Liao, Jihyun R. Stephans, Dylan K. Chan

    Objective: To identify sociodemographic factors associated with pediatric late‐identified hearing loss (LIHL) and classify novel subgroups within the LIHL population.Study Design: Retrospective cohort.Setting: Tertiary children's hospital.Methods: Our cohort included children with permanent hearing loss (HL) between 2012 and 2020 (n = 1087). Patients with early‐identified HL were compared to patients with LIHL (>6 months of age at diagnosis), and 3 subgroups: (1) late‐identified congenital HL: failed NHS but had a diagnostic audiogram >6 months old; (2) late‐onset HL: passed NHS and identified with HL after 6 months old; (3) late‐identified, unknown‐onset: unknown NHS results, identified after 6 months old. Geospatial analysis was performed using ArcGIS Pro.Results: Compared with early‐identified children, children with LIHL were more likely to have more comorbidities (odds ratio [OR] = 1.12, [1.01, 1.23]), be an under‐represented minority (URM) (OR = 1.92, [1.27, 2.93]) and have a higher social vulnerability index (SVI) (adjusted odds ratio [AOR] = 2.1, [1.14, 3.87]). However, subgroups in the LIHL cohort had variable associations. Children with late‐identified unknown onset hearing loss were uniquely associated with a primarily non‐English speaking household (AOR = 1.84, [1.04, 3.25]), whereas children with late‐onset hearing loss were less likely to have public insurance (AOR = 0.47, [0.27, 0.81]. There were no significant associations for children with late‐identified congenital hearing loss. Neighborhood disadvantage, as measured by SVI, had an increased association with late‐identified unknown onset HL (AOR = 4.08, [2.01, 8.28]) and a decreased association with late‐onset HL (AOR = 0.40, [0.22, 0.72]).Conclusion: Sociodemographic factors serve as proxies for health care access, and these factors vary across LIHL pathways. Understanding the risk factors associated with each LIHL subgroup may help address disparities in pediatric HL identification.


  • Race and Ethnicity in Otolaryngology Academic Publications

    by Michael Lindeborg, Taseer Din, Cristóbal Araya‐Quezada, Sabreena Lawal, Baveena Heer, Praveen Rajaguru, Myriam Joseph, Blake Alkire, Johannes Fagan

    Objective: Within otolaryngology, race is commonly included as a study covariate; however, its value in clinical practice is unclear. This study sought to explore how race and ethnicity have been used and applied over time in otolaryngology publications.Data Sources: PubMed database.Review Methods: A systematic review was done to identify original otolaryngology studies between January 1, 1946, and June 25, 2020, with the following search terms: “otolaryngology” AND “race” OR “ethnicity.”Results: Of the 1984 yielded studies, 932 were included in the final analysis. Only 2 studies (0.2%) defined race, and 172 (18.5%) gave participants the opportunity to self‐identify race. Less than half (n = 322, 43.8%) of studies controlled for confounders. One hundred studies (10.7%) linked race to genetic factors. An overall 564 (60.5%) made conclusions about race, and 232 (24.9%) mentioned that race is relevant for clinical decision making. The majority of studies had first and senior authors from high‐income countries (93.9% and 93.8%, respectively). Over time, there was a significant increase in publications that controlled for confounders, the number of race categories used, and studies that highlighted disparities.Conclusion: Race and ethnicity are often poorly defined in otolaryngology publications. Furthermore, publications do not always control for confounding variables or allow participants to self‐identify race. On the basis of our findings, we suggest 7 foundational principles that can be used to promote equitable research in otolaryngology publications. Future efforts should focus on incorporating research guidelines for race and ethnicity into journal publication standards.


  • Open Access

    Predicting length of stay in head and neck patients who undergo free flap reconstruction

    by Michael M. Lindeborg, Rosh K. V. Sethi, Sidharth V. Puram, Anuraag Parikh, Bharat Yarlagadda, Mark Varvares, Kevin Emerick, Derrick Lin, Marlene L. Durand, Daniel G. Deschler

    Objective: Understanding factors that affect postoperative length of stay (LOS) may improve patient recovery, hasten postoperative discharge, and minimize institutional costs. This study sought to (a) describe LOS among head and neck patients undergoing free flap reconstruction and (b) identify factors that predict increased LOS.Methods: A retrospective cohort was performed of 282 head and neck patients with free flap reconstruction for oncologic resection between 2011 and 2013 at a tertiary academic medical center. Patient demographics, tumor characteristics, and surgical and infectious complications were characterized. Multivariable regression identified predictors of increased LOS.Results: A total of 282 patients were included. Mean age was 64.7 years (SD = 12.2) and 40% were female. Most tumors were located in the oral cavity (53.9% of patients), and most patients underwent radial forearm free flap (RFFF) reconstruction (RFFF—73.8%, anterolateral thigh flap—11.3%, and fibula free flap—14.9%). Intraoperative complications were rare. The most common postoperative complications included nonwound infection (pneumonia [PNA] or urinary tract infection [UTI]) (15.6%) and wound breakdown/fistula (15.2%). Mean and median LOS were 13 days (SD = 7.7) and 10 days (interquartile range = 7), respectively. Statistically significant predictors of increased LOS included flap take back (Beta coefficient [C] = +4.26, P < .0001), in‐hospital PNA or UTI (C = +2.52, P = .037), wound breakdown or fistula (C = +5.0, P < .0001), surgical site infection (C = +3.54, P = .017), and prior radiation therapy (C = +2.59, P = .004).Conclusion: Several perioperative factors are associated with increased LOS. These findings may help with perioperative planning, including the need for vigilant wound care, optimization of antibiotics prophylaxis, and institution‐level protocols for postoperative care and disposition of free flap patients.Level of Evidence: 2b; retrospective cohort.


  • Predictive factors for prolonged operative time in head and neck patients undergoing free flap reconstruction

    by Michael M. Lindeborg, Sidharth V. Puram, Rosh K.V. Sethi, Nicholas Abt, Kevin S. Emerick, Derrick Lin, Daniel G. Deschler


  • Nepali Linguistic Validation of the Velopharyngeal Insufficiency Effects on Life Outcomes Instrument: VELO-Nepali

    by Michael M. Lindeborg, Pramila Shakya, Bhawani Pradhan, Shiba Kala Rai, Kabita Bhattarai Gurung, Suman Niroula, Badri Rayamajhi, Hema Chaudhary, Bhagwati Gaire, Naina Mahato, et al.

    To translate and validate the velopharyngeal insufficiency (VPI) effects on life outcomes (VELO) instrument into Nepali, and test its internal consistency and validity. Quality-of-life instrument translation and validation. Community served by Nepal’s craniofacial referral hospital. Twenty-three postpalatoplasty children with VPI, 19 family guardians of VPI cases, and 29 non-VPI controls. The VELO instrument was translated to Nepali by 2 independent bilingual translators, reconciled, backward-translated, compared, and modified using patient cognitive interviews. All VPI children, guardians, and controls completed the VELO-Nepali. The VELO internal consistency was evaluated using Cronbach α coefficient. Concurrent validity and discriminant validity were assessed using 2-sample t test: assuming unequal variances. The VELO was translated and optimized using cognitive interviews. The VELO-Nepali demonstrated excellent internal consistency, with Cronbach α coefficients of 0.93, 0.94, and 0.90 for VPI cases, guardians of VPI cases, and non-VPI controls, respectively. The VELO-Nepali exhibited strong discriminant validity between VPI cases (x¯ = 45.4, standard deviation [SD] = 22.1) and non-VPI controls (x¯ = 84.9, SD = 12.3), (P < .001). The VELO-Nepali showed strong concurrent validity with similarities in VPI case scores (x¯ = 45.4, SD = 22.1), and guardian scores (x¯ = 52.9, s = 22.8; P = .473). The translated VELO-Nepali demonstrates strong internal consistency, discriminant validity, and concurrent validity, and can assess quality of life for Nepali VPI patients. This instrument represents the first VPI quality of life assessment validated in Nepali, and supports the feasibility of its implementation in other low- and low-middle-income countries.


  • The fourth national anti-tuberculosis drug resistance survey in Peru

    by N. Quispe, L. Asencios, C. Obregon, G. E. Velásquez, C. D. Mitnick, M. Lindeborg, H. Jave, L. Solari

    BACKGROUND: Peru has one of the highest burdens of multidrug-resistant tuberculosis (MDR-TB), but universal drug susceptibility testing (DST) has not yet been achieved.OBJECTIVE: To estimate the proportion of drug resistance among smear-positive TB patients in Peru.DESIGN: From September 2014 to March 2015, we performed a national drug resistance survey of patients aged ≥15 years; TB was diagnosed based on sputum smear positivity. We performed DST at the National Reference Laboratory of the Peruvian National Institute of Health, Lima, Peru, using the proportion method in Middlebrook 7H10 agar for four first-line drugs and six second-line drugs, and the Wayne method for pyrazinamide.RESULTS: Of the 1908 new and 272 previously treated patients included in the analysis, 638 (29.3%) patients had resistance to at least one first-line drug. MDR-TB was diagnosed in 7.3% of new and 16.2% of previously treated patients (P < 0.001). There were five (0.2%) patients with extensively drug-resistant TB.CONCLUSION: MDR-TB has increased to 7.3% in new patients from 5.3% in the previous survey, indicating that resistance to anti-tuberculosis drugs is increasing in Peru. Ongoing community transmission of resistant strains highlights an urgent need for early diagnosis, optimised treatment and effective contact tracing of MDR-TB patients.


  • Global Cash Flows for Sustainable Development: A Case Study of Accountability and Health Systems Strengthening in Lesotho

    by Joia Mukherjee, Michael M. Lindeborg, Sandhira Wijayaratne, Carole Mitnick, Paul E. Farmer, Hind Satti

    Despite high health expenditures, Lesotho had some of the world's worst health indicators between 2000 and 2014. Official development assistance tripled from $37 to $107 million. PEPFAR funding rose from $3.8 to $32.4 million. Yet, deaths from TB, HIV, infant mortality, and maternal mortality remained unchanged. Lesotho had declining health outcomes amidst increased disease-focused financing and several large infrastructure projects. A World Bank loan financed the state-of-the-art Mamohato Hospital, and the U.S.-supported $362.5 million Millennium Challenge Corporation Project supported primary and secondary health infrastructure. This analysis uses the WHO Health Systems Framework to explore the unintended consequences of health financing on Lesotho's health outcomes. The WHO Health Systems Framework can be used to optimize health financing through investments in health service delivery, health workforce, health information, essential medicines, leadership, and equitable financial strategies. This approach can support governments to achieve universal health coverage and develop comprehensive health systems.


  • Emotional Experiences of Mothers Living With HIV and the Quest for Emotional Recovery

    by Carmen Contreras, Nancy Rumaldo, Michael Masao Lindeborg, Milagros Mendoza, David Roy Chen, Olga Saldaña, Milagros Wong, Maribel Muñoz, Elizabeth Schrier, Leonid Lecca, et al.

    Little evidence exists about the emotional experiences of mothers with HIV, and a better understanding is essential to support their emotional health and treatment adherence. We describe the emotional experiences of eight mothers who initiated antiretroviral therapy during pregnancy or within a few years of childbirth in Lima, Peru. An interpretive phenomenological approach was used, and the following themes emerged: (a) emotions involved in diagnosis and disclosure, (b) the meaning of motherhood with HIV, (c) the mothers' roles in seeking and maintaining relationships with partners and families, and (d) mechanisms for resilience and emotional recovery. Participants experienced sadness and denial after diagnosis, which gave way to emotional recovery. Participant abilities to find refuge in caring for children and coordinating support from loved ones proved to be essential. Participants recognized that intense emotions motivated them to seek creative solutions and cited personal growth as an important outcome.